


HALICHONDRIN B ANALOGS

Related Applications

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 61/042,643, filed April 4, 2008, and U.S. Provisional Application No. 61/071,111, filed April 11, 2008, both of which are herein incorporated by reference in their entirety.

Field of the Invention

[0002] This invention relates to halichondrin B analogs having pharmaceutical activity. In some embodiments, the analogs have a crystalline form and/or have a further utility as a synthetic intermediate in the synthesis of the halichondrin B analog E7389, a compound having potent anticancer properties.



Background of the Invention

[0003] Halichondrin B, a potent anticancer agent, was first isolated from the marine sponge *Halichondria okadai*. It is also found in *Axinella* sp., *Phakellia carteri*, and *Lissonodendryx* sp. Halichondrin B has demonstrated *in vitro* inhibition of tubulin polymerization, microtubule assembly, beta^S-tubulin crosslinking, GTP and vinblastine binding to tubulin, and tubulin-dependent GTP hydrolysis. It has also shown *in vitro* and *in vivo* anticancer activity.

[0004] Aicher, et al. published a total synthesis of halichondrin B in 1992. See Aicher, T. D. et al., *J. Am. Chem. Soc.* 114:3162-3164, and Zheng, W. J. et al., *J. Bioorg. Med. Chem. Lett.* 2004, 14, 5551. The syntheses of halichondrin B and various analogs have also been

described in U.S. patents 6,214,865; 6,365,759; 6,469,182; and 6,653,341; in U.S. published patent applications 2004/0198806 and 2006/0104984; and in PCT published application WO 2005/118565, all of which are herein incorporated by reference in their entirety.

Summary of the Invention

[0005] This invention relates to halichondrin B analogs having pharmaceutical activity. The analogs have a crystalline form and/or have a further utility as a synthetic intermediate in the synthesis of the halichondrin B analog E7389, a compound having potent anticancer properties. Accordingly, the invention relates to a crystalline form of ER-076349 monohydrate; a crystalline form of ER-809681; the compound ER-820057 or a crystalline form of ER-820057; the compound ER-818906 or a crystalline form of ER-818906; the compound ER-819531 or a crystalline form of ER-819531; and the compound ER-111197 or a crystalline form of ER-111197. The invention also relates to pharmaceutical compositions containing these compounds, and methods of treating cancer by administering the compounds.

Brief Description of Figures

[0006] Fig. 1-A is an ORTEP drawing of the single crystal structure of ER-076349-00 monohydrate.

[0007] Fig. 1-B is the crystal packing diagram of ER-076349 monohydrate along the b-axis.

[0008] Fig. 1-C is the X-ray Powder Diffraction (XRPD) pattern of ER-076349 monohydrate crystallized from isopropyl alcohol.

[0009] Fig. 1-D is a plot of XRPD patterns of ER-076349 monohydrate from various solvents.

[0010] Fig. 1-E is a plot of the DSC of ER-076349 monohydrate crystallized from ethanol.

[0011] Fig. 1-F is a plot of the DSC of ER-076349 monohydrate crystallized from isopropanol.


[0012] Fig. 1-G is a plot of the DSC of ER-076349 monohydrate crystallized from propionitrile.

[0013] Fig. 2-A is an ORTEP drawing of the single crystal structure of ER-818906 mono-acetonitrile solvate.


- [0014] Fig. 2-B is the crystal packing diagram of ER-818906 monoacetonitrile solvate along the c-axis.
- [0015] Fig. 2-C is the XRPD pattern of ER-818906 (epi-C20 diol) mono-acetonitrile solvate.
- [0016] Fig. 3-A is an ORTEP drawing of the single crystal structure of ER-819531 (epi-C23 diol) monohydrate.
- [0017] Fig. 3-B is the crystal packing diagram of ER-819531 (epi-C23 diol) monohydrate along the b-axis.
- [0018] Fig. 3-C is the XRPD pattern of ER-819531 (epi-C23 diol)
- [0019] Fig. 4-A is the XRPD pattern of ER-820057 (epi-C23 amine).
- [0020] Fig. 5-A is an ORTEP drawing of the single crystal structure of ER-111197 (epi-C34 diol) monohydrate.
- [0021] Fig. 5-B is the crystal packing diagram of ER-111197 (epi-C34 diol) monohydrate along the a-axis.
- [0022] Fig. 6-A is an ORTEP drawing of the single crystal structure of ER-809681 (epoxide).
- [0023] Fig. 6-B is the crystal packing diagram of ER-809681 (epoxide) along the b-axis.
- [0024] Fig. 6-C is the XRPD pattern of ER-809681 (epoxide).
- [0025] Fig. 6-D is the calculated XRPD pattern of ER-809681 (epoxide).

Detailed Description of Invention

[0026] As described in U.S. Patent 6,214,865, the halichondrin B analog, ER-086526 (identified as compound B-1939), is a potent antitumor agent. ER-086526 is prepared from an intermediate diol compound, ER-076349 (identified as compound B-1793). U.S. Patent 6,214,865 describes the preparation of ER-076349 (B-1793) as well as its use in the preparation of several other halichondrin B analogs.




ER-086526




ER-076349

[0027] An alternative synthetic route to ER-086526 via ER-076349 is described in PCT published application WO 2005/118565. According to WO 2005/118565, ER-076349 is converted into ER-086526 as follows:




[0028] In the WO 2005/118565 process, ER-076349 is reacted to form a tosylate *in situ*, ER-082892, which then converts to an epoxide *in situ*, ER-809681, before forming ER-086526, as shown in the following scheme:




ER-076349

Ts₂O, Collidine,
Pyridine, DCM




ER-082892
Not isolated

Water, NH₄OH, IPA



ER-809681
Not isolated



ER-088526

Water, NH₄OH, IPA

[0029] ER-076349 crystallizes from various solvents as a monohydrate. The epoxide, ER-809681, may also be isolated as a crystalline compound. Crystalline ER-076349 monohydrate (example 1) and crystalline ER-809681 (example 6) represent separate embodiments of this invention.

[0030] In multi-step syntheses, such as those described in U.S. Patent No. 6,214,865 and WO 2005/118565, intermediates are prepared and unwanted by-products or impurities can be carried forward from earlier steps. Often filtration, separation, and/or purification steps are introduced to remove unwanted by-products or impurities. Incorporating such steps not only can increase costs but can decrease the overall yield of the synthesis. Having a crystalline intermediate within a multi-step synthesis can address these problems. A crystalline intermediate provides certain advantages—a high purity intermediate can reduce the need for other purification steps and reduce the cost of the synthetic process. In the preparation of ER-086526, having crystalline ER-076349 monohydrate as a high purity intermediate allows separation from its C25 epimer. In the bulk crystalline ER-076349, the amount of the C25 epimer is generally below 0.1 wt%.

[0031] This invention also relates to crystalline forms of certain diastereomers of ER-076349. One or more diastereomers are common impurities occurring in the multi-step synthesis of compounds having several chiral carbon atoms. It is useful to characterize the various diastereomers in order to identify the epimeric impurities which occur, or might occur, in the preparation of the desired compound. Identifying an epimeric impurity can lead to process improvements to reduce, avoid, quantify, or remove the impurity. Crystalline forms of the various epimers allows for specific characterization of the particular epimer and its identification in the synthesis. In addition, crystallization of a particular epimer can be a means of removing it and thereby purifying the desired compound. Crystalline forms of epimers of ER-076349 address these needs in the synthesis of ER-086526. Crystalline forms of the following compounds, related to ER-076349, represent further embodiments of this invention: ER-809681; ER-820057; ER-818906; ER-819531; and ER-111197, all of which exhibit anti-cancer activity. This group of compounds and crystalline forms of the compounds is collectively referred to as halichondrin B analogs and individually referred to as a halichondrin B analog for this purposes of this disclosure.

[0032] There are numerous types of anti-cancer approaches that can be used in conjunction with halichondrin B analog treatment, according to the invention. These include, for example, treatment with chemotherapeutic agents (see below), biological agents (e.g., hormonal agents, cytokines (e.g., interleukins, interferons, granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), and granulocyte macrophage colony stimulating factor (GM-CSF)), chemokines, vaccine antigens, and antibodies), anti-angiogenic agents (e.g., angiostatin and endostatin), radiation, and surgery.

[0033] The methods of the invention can employ these approaches to treat the same types of cancers as those for which they are known in the art to be used, as well as others, as can be determined by those of skill in this art. Also, these approaches can be carried out according to parameters (e.g., regimens and doses) that are similar to those that are known in the art for their use. However, as is understood in the art, it may be desirable to adjust some of these parameters, due to the additional use of a halichondrin B analog with these approaches. For example, if a drug is normally administered as a sole therapeutic agent, when combined with a halichondrin B analog, according to the invention, it may be desirable to decrease the dosage of the drug, as can be determined by those of skill in this art. Examples of the methods of the invention, as well as compositions that can be used in these methods, are provided below.

[0034] Chemotherapeutic drugs of several different types including, for example, antimetabolites, antibiotics, alkylating agents, plant alkaloids, hormonal agents, anticoagulants, antithrombotics, and other natural products, among others, can be used in conjunction with halichondrin B treatment, according to the invention. Specific, non-limiting examples of these classes of drugs, as well as cancers that can be treated by their use, are as follows.

[0035] Antimetabolite drugs that halichondrin B analogs can be used with include, e.g., methotrexate, purine antagonists (e.g., mercaptopurine, thioguanine, fludarabine phosphate, cladribine, and pentostatin), and pyrimidine antagonists (e.g., gemcitabine, capecitabine, fluorouracil (e.g., 5-FU), cytarabine, and azacitidine). Use of these agents to treat particular types of cancers is well known in the art, and these agents can be used in combination with halichondrin B analogs to treat these and other types of cancers. As specific, non-limiting examples, a halichondrin B analog can be used with gemcitabine in the treatment of non-small cell lung carcinoma, pancreatic cancer, or metastatic breast cancer. In an additional example, a

halichondrin B analog can be used in conjunction with capecitabine in the treatment of breast or colorectal cancers.

[0036] As is noted above, another class of chemotherapeutic drugs with which halichondrin B analogs can be used includes anticancer antibiotics. These include, for example, anthracyclines (e.g., doxorubicin, epirubicin, daunorubicin, and idarubicin), adriamycin, dactinomycin, idarubicin, plicamycin, mitomycin, and bleomycin. As with the drugs mentioned above, use of these agents to treat particular types of cancers is well known in the art, and they can be used in combination with halichondrin B analog treatment to treat these and other types of cancers. As a specific, non-limiting example, an anthracycline, such as doxorubicin, can be administered in conjunction with halichondrin B therapy for the treatment of breast or pancreatic cancers. Alternatively, a third agent, cyclophosphamide, can be used in this method.

[0037] Alkylating agents comprise another class of chemotherapeutic drugs that can be administered in conjunction with a halichondrin B analog, according to the invention. Examples of such drugs include procarbazine, dacarbazine, altretamine, cisplatin, carboplatin, and nitrosoureas. Halichondrin B analogs can be used with these agents in the treatment of cancers that these agents are known in the art to be used to treat, as well as in the treatment of other cancers. For example, a halichondrin B analog can be used in conjunction with carboplatin in the treatment of non-small cell lung carcinoma or ovarian cancer.

[0038] An additional type of chemotherapeutic drug with which halichondrin B analogs can be administered, according to the invention, is plant alkaloids, such as vinblastine, vincristine, etoposide, teniposide, topotecan, irinotecan, paclitaxel, and docetaxel. As specific, non-limiting examples, a halichondrin B analog can be used in conjunction with irinotecan for the treatment of colorectal cancer, or with topotecan in the treatment of ovarian or non-small cell lung cancers.

[0039] Further types of anti-cancer agents that can be used in conjunction with halichondrin B analog treatment, according to the invention, are anticoagulants and antithrombotic agents. For example, heparin (e.g., low molecular weight heparin or heparin sulfate) or warfarin can be used. Use of these agents in treating patients by, for example, injection or oral administration, is well known in the art, and thus they can readily be adapted by those of skill in the art for use in the present invention.

[0040] Numerous approaches for administering anti-cancer drugs are known in the art, and can readily be adapted for use in this invention. In the case of one or more drugs that are to be administered in conjunction with a halichondrin B analog, for example, the drugs can be administered together, in a single composition, or separately, as part of a comprehensive treatment regimen. For systemic administration, the drugs can be administered by, for example, intravenous infusion (continuous or bolus). Appropriate scheduling and dosing of such administration can readily be determined by those of skill in this art based on, for example, preclinical studies in animals and clinical studies (e.g., phase I studies) in humans. In addition, analysis of treatment using similar drugs, as well as monitoring factors such as blood counts (e.g., neutrophil and platelet counts) and vital signs in patients can be used, as is well understood in the art.

[0041] Many regimens used to administer chemotherapeutic drugs involve, for example, intravenous administration of a drug (or drugs) followed by repetition of this treatment after a period (e.g., 1-4 weeks) during which the patient recovers from any adverse side effects of the treatment. It may be desirable to use both drugs at each administration or, alternatively, to have some (or all) of the treatments include only one drug (or a subset of drugs).

[0042] As a specific, non-limiting example of a treatment regimen included in the invention, a halichondrin B analog (e.g., 0.01-5 mg/m²) can be administered to a patient by intravenous infusion for 0.5-3 hours, followed by intravenous infusion of another drug (e.g., gemcitabine, e.g., 500-900 mg/m²) for 0.5-3 hours. This course of treatment can be repeated every 2-3 weeks, as determined to be tolerable and effective by those of skill in the art. In a variation of this method, the treatment is carried out with both drugs on the first day, as is noted above, but then is followed up with treatment using only the secondary drug (e.g., gemcitabine) in ensuing weeks.

[0043] Further, as is well known in the art, treatment using the methods of the invention can be carried out in conjunction with the administration of antiemetics, which are drugs that are used to reduce the nausea and vomiting that are common side effects of cancer chemotherapy. Examples of such drugs include major tranquilizers (e.g., phenothiazines, such as chlorpromazine and prochlorperazine), dopamine antagonists (e.g., metoclopramide), serotonin antagonists (e.g., ondansetron and granisetron), cannabinoids (e.g., dronabinol), and benzodiazepine sedatives.

[0044] In addition to the cancers mentioned above, the methods and compositions of the invention can be used to treat the following types of cancers, as well as others: skin (e.g., squamous cell carcinoma, basal cell carcinoma, or melanoma), prostate, brain and nervous system, head and neck, testicular, lung, liver (e.g., hepatoma), kidney, bladder, gastrointestinal, bone, endocrine system (e.g., thyroid and pituitary tumors), and lymphatic system (e.g., Hodgkin's and non-Hodgkin's lymphomas) cancers. Other types of cancers that can be treated using the methods of the invention include fibrosarcoma, neurectodermal tumor, mesothelioma, epidermoid carcinoma, and Kaposi's sarcoma.

[0045] The invention also includes compositions that include a halichondrin B analog in combination with an additional therapeutic agent(s), such as any of those agents listed above. The drugs in these compositions preferably are formulated for administration to patients (e.g., in physiological saline) or, alternatively, can be in a form requiring further processing prior to administration. For example, the compositions can include the drugs in a lyophilized form or in a concentrated form requiring dilution. Formulation of drugs for use in chemotherapeutic methods can be carried out using standard methods in the art (see, e.g., Remington's Pharmaceutical Sciences (18th edition), ed. A. Gennaro, 1990, Mack Publishing Co., Easton, Pa.).

[0046] **Examples**

[0047] **Single Crystal X-ray Diffraction Data Collection and Structure Determinations**

[0048] Data were collected using a Bruker SMART APEX CCD (charge coupled device) based diffractometer equipped with an Oxford Cryostream low-temperature apparatus operating at 193 K. Data were measured using omega scans of 0.3 ° per frame for 30 seconds, such that a hemisphere was collected. A total of 1271 frames were collected with a maximum resolution of 0.76 Å. The first 50 frames were recollected at the end of data collection to monitor for decay. Cell parameters were retrieved using SMART software (SMART V 5.625 (NT) *Software for the CCD Detector System*; Bruker Analytical X-ray Systems, Madison, WI (2001)). and refined using SAINT on all observed reflections. Data reduction was performed using the SAINT software (SAINT V 6.22 (NT) *Software for the CCD Detector System* Bruker Analytical X-ray Systems, Madison, WI (2001). which corrects for Lp and decay. The structures were solved by the direct method using the SHELXS-97 program (Sheldrick, G. M.

SHELXS-90, *Program for the Solution of Crystal Structure*, University of Göttingen, Germany, 1990.) and refined by least squares method on F^2 , SHELXL-97, (Sheldrick, G. M. SHELXL-97, *Program for the Refinement of Crystal Structure*, University of Göttingen, Germany, 1997.) incorporated in SHELXTL-PC V 6.10, (SHELXTL 6.1 (PC-Version), *Program library for Structure Solution and Molecular Graphics*; Bruker Analytical X-ray Systems, Madison, WI (2000)).

[0049] X-ray Powder Diffraction (XRPD) Data Collection Procedure

[0050] A small amount of crystalline material was used for the XRPD diffraction studies described below. The material was not crushed, and so may have preferred orientation effects. Using a quartz plate, on the Scintag Diffractometer. Data was acquired under normal powder diffraction condition, with 2-theta range of 5-70 degrees, using copper radiation. No background correction was applied. Table 1 lists the data acquisition parameters.

Table 1. XRPD Measurement Conditions

X-ray diffractometer:	Scintag
Target:	Cu
Detector:	Lithium Drifted Diode
Tube voltage:	40 kV
Tube current:	30 mA
Slit:	DS 1.0, RS 0.3 mm, SS 2 mm tube, 0.5mm detector
Scan speed:	1 °/min
Step/Sampling:	0.02 °
Scan range:	5 to 70 °
Sample holder:	Quartz holder (25 mm x 25 mm)
Goniometer:	Theta-Theta, fixed horizontal mount, goniometer
Filter:	Electronic
Monochromator:	not used

[0051] Example 1: Characterization of Crystalline ER-076349 Monohydrate

[0052] XRPD patterns of ethanol, isopropanol (IPA), propionitrile are identical to acetonitrile/water sample. Characterization as monohydrate was based on this comparison. X-ray unit cell of acetonitrile/water crystal clearly showed the presence of single water molecule.

[0053] A. Crystallization Procedures for ER-076349 Monohydrate

[0054] Crystallization of ER-076349 from ethanol, isopropanol, and propionitrile (XRPD sample): ER-076349 was dissolved in solvent (5 vol). The solution was allowed to evaporate at room temperature and a crystal suitable for XRPD testing formed over 16 to 24 hr.

[0055] Crystallization of ER-076349 from acetonitrile/water solution (XRPD sample): ER-076349 was dissolved in acetonitrile (1 vol). To this solution was slowly added a water/acetonitrile solution (10 vol, 2 parts water, 1 part acetonitrile); if the solution becomes cloudy, a minimal amount of acetonitrile can be added. The solution was seeded with ER-076349 (0.004 wts). The mixture is stirred at room temperature and the solvent evaporated under inert gas flow until the acetonitrile level is $\leq 5\%$. The solids were slurried in water (5 vol) and the mixture was filtered. The filtered solids were dried under high vacuum and inert gas flow for 12 to 24 hours.

[0056] Crystallization of ER-076349 from acetonitrile/water solution (single crystal): ER-076349 was dissolved in acetonitrile (5 vol). Water (0.5 vol) was then added. The container was stored at room temperature and vented for slow evaporation of solvent for 4 weeks, and the single crystal suitable for X-ray structure study formed slowly.

[0057] B. Single Crystal X-Ray Determination of ER-076349 Monohydrate

[0058] A colorless plate crystal with dimensions 0.10 x 0.10 x 0.04 mm was mounted on a 0.2 mm nylon loop using very small amount of paratone oil. The single crystal structure, shown in Fig. 1-A, was determined using the procedure described above. Table 2 lists the crystal data and structure refinement parameters used to determine the single crystal structure of ER-076349 monohydrate. The structure was solved in the space group $P2_12_12_1$ (# 19) by analysis of systematic absences. All non-hydrogen atoms were refined anisotropically. Hydrogens were calculated by geometrical methods and refined as a riding model. The crystal used for

the diffraction study showed no decomposition during data collection. All drawings were done at 50% ellipsoids. Fig. 1-B is the crystal packing diagram of ER-076349 monohydrate along the b-axis, which shows the best diagram of the hydrogen bonding within the crystal, dotted lines.

Table 2. Crystal data and structure refinement for ER-076349 Monohydrate.

Empirical formula	$C_{40}H_{59}O_{13}$	
Formula weight	747.87	
Temperature	193(2) K	
Wavelength	0.71073 Å	
Crystal system	Orthorhombic	
Space group	P2(1)2(1)2(1)	
Unit cell dimensions	$a = 9.9189(14)$ Å	$\alpha = 90^\circ$.
	$b = 11.3394(17)$ Å	$\beta = 90^\circ$.
	$c = 34.029(5)$ Å	$\gamma = 90^\circ$.
Volume	$3827.3(10)$ Å ³	
Z	4	
Density (calculated)	1.298 Mg/m ³	
Absorption coefficient	0.096 mm ⁻¹	
F(000)	1612	
Crystal size	0.10 x 0.10 x 0.04 mm ³	
Theta range for data collection	1.20 to 26.39°.	
Index ranges	$-10 \leq h \leq 12$, $-13 \leq k \leq 14$, $-32 \leq l \leq 42$	
Reflections collected	23198	
Independent reflections	7808 [R(int) = 0.1131]	
Completeness to theta = 26.39°	99.9 %	
Absorption correction	None	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	7808 / 0 / 482	
Goodness-of-fit on F ²	0.938	
Final R indices [I > 2sigma(I)]	R1 = 0.0627, wR2 = 0.0911	
R indices (all data)	R1 = 0.1693, wR2 = 0.1150	
Absolute structure parameter	-0.7(12)	
Largest diff. peak and hole	0.380 and -0.182 e.Å ⁻³	

[0059] C. X-ray Powder Diffraction (XRPD) Characterization of ER-076349 Monohydrate

[0060] Fig. 1-C is the XRPD pattern of ER-076340 monohydrate crystallized from isopropyl alcohol as described above. Table 3 shows the list of peaks with relative intensities in the XRPD pattern.

Table 3. XRPD Peaks of ER-076349 monohydrate	
Position (2 θ)	Rel. Int. (%)
18.2	100.0%
20.8	91.0%
18.7	60.3%
20.3	59.6%
10.4	59.3%
22.2	51.2%
15.9	42.5%
13.0	37.4%
9.3	37.1%
14.2	35.5%
12.1	29.3%
11.9	28.3%
5.2	22.9%


[0061] Fig. 1-D is a stacked plot of representative XRPD patterns of ER-076349 monohydrate acquired from various recrystallization solvents, including acetonitrile and water, ethanol, isopropanol, and propionitrile. The same method of pattern acquisition as described above was used.

[0062] Figs. 1-E, 1-F, and 1-G depict differential scanning calorimetry (DSC) thermograms of ER-076349 monohydrate. Fig. 1-E depicts a plot of the DSC of ER-076349 crystallized from ethanol solution. The DSC shows an endothermic peak at 160 °C. Fig. 1-F depicts a plot of the DSC of ER-076349 crystallized from isopropanol solution. The DSC shows an endothermic peak at 157 °C. Fig. 1-G depicts a plot of the DSC of ER-076349 crystallized from propionitrile solution. The DSC shows an endothermic peak at 161 °C.

[0063] **Example 2: Characterization of ER-818906 (epi-C20 diol) , a Mono-Acetonitrile Solvate**

[0064] **A. Crystallization procedure for generation of X-ray and XRPD crystal samples**

[0065] ER-818906 (1 wt) was suspended in acetonitrile (10 vol) and warmed gently to ensure complete dissolution. The solution was held at room temperature and crystal growth initiated after 30 minutes. The single crystal sample suitable for X-ray structure analysis formed after 16 to 24 hours. The chemical structure of ER-818906 (epi-C20 diol) is shown below.



ER-818906
(Epi-C20 Diastereomer)

[0066] **B. Single Crystal X-Ray Determination of ER-818906 (epi-C20 diol) Mono-Acetonitrile Solvate**

[0067] A colorless block crystal with dimensions 0.12 x 0.12 x 0.10 mm was mounted on a 0.2 mm nylon loop using very small amount of paratone oil. The single crystal structure, shown in Fig. 2-A, was determined using the procedure described above. Table 3 lists the crystal data and structure refinement parameters used to determine the single crystal structure of ER-818906 mono-acetonitrile solvate. The structure was solved in the space group $P2_1$ (#4). All non-hydrogen atoms were refined anisotropically. Hydrogens were calculated by geometrical methods and refined as a riding model. The Flack parameter was used to analyze the crystal. If the Flack parameter value is near zero, the absolute structure given by the structure element refinement is likely correct; if the value is near 1.0, then the inverted structure (the other enantiomer) is likely correct; if the value is near 0.5, the crystal is likely racemic. See Flack, H. D., *Acta Cryst. A* 39, 1983, 876--881. The Flack parameter was refined to 0.3(4). The chirality of this compound was confirmed by its synthetic source. The crystal

used for the diffraction study showed no decomposition during data collection. All drawing are done at 50% ellipsoids. Fig. 2-B is the crystal packing diagram of ER-818906 monoacetonitrile solvate along the c-axis.

Table 3. Crystal data and structure refinement for ER-818906 Mono-Acetonitrile Solvate.

Empirical formula	$C_{42}H_{61}NO_{12}$	
Formula weight	771.92	
Temperature	193(2) K	
Wavelength	0.71073 Å	
Crystal system	Monoclinic	
Space group	P2(1)	
Unit cell dimensions	$a = 10.610(4)$ Å	$\alpha = 90^\circ$.
	$b = 17.114(7)$ Å	$\beta = 94.341(7)^\circ$.
	$c = 11.251(5)$ Å	$\gamma = 90^\circ$.
Volume	$2036.9(15)$ Å ³	
Z	2	
Density (calculated)	1.259 Mg/m ³	
Absorption coefficient	0.091 mm ⁻¹	
F(000)	832	
Crystal size	$0.12 \times 0.12 \times 0.10$ mm ³	
Theta range for data collection	1.82 to 27.87° .	
Index ranges	$-13 \leq h \leq 12$, $-22 \leq k \leq 22$, $-14 \leq l \leq 14$	
Reflections collected	14960	
Independent reflections	9147 [$R(\text{int}) = 0.0160$]	
Completeness to $\theta = 27.87^\circ$	98.6 %	
Absorption correction	EMPIRICAL	
Max. and min. transmission	0.9909 and 0.9891	
Refinement method	Full-matrix least-squares on F^2	
Data / restraints / parameters	9147 / 1 / 501	
Goodness-of-fit on F^2	1.044	
Final R indices [$I > 2\sigma(I)$]	$R1 = 0.0410$, $wR2 = 0.0881$	
R indices (all data)	$R1 = 0.0473$, $wR2 = 0.0909$	
Absolute structure parameter	0.3(6)	
Largest diff. peak and hole	0.222 and -0.199 e.Å ⁻³	

[0068] C. X-ray Powder Diffraction (XRPD) Characterization of ER-818906 (epi-C20 diol) Mono-Acetonitrile Solvate


[0069] A small amount of material was left after removing a sample for single crystal study in Example 2A. The XRPD pattern was obtained as described above. The XRPD pattern is shown in Fig. 2-C. Table 4 shows the list of peaks with relative intensities in the XRPD pattern.

Table 4. XRPD Peaks of ER-818906 (epi-C20 diol)	
Position (2 θ)	Rel. Int. (%)
23.7	100.0
32.8	35.6
7.9	25.0
40.0	19.4
68.4	14.5
23.9	12.2
29.2	10.4
26.7	7.7
8.1	7.3
48.6	7.2
57.5	6.4
48.9	5.9
40.7	5.7
34.1	4.0

[0070] Example 3: Characterization of ER-819531 (epi-C23 diol) Monohydrate

[0071] A. Crystallization procedure for XRPD quality sample

[0072] ER-819531 (1 wt) was dissolved in acetonitrile (10 vol) at room temperature and the temperature was decreased to -20 °C and held at this temperature for 16 hours. Clusters of crystal suitable for powder XRPD test formed after 16 hours. The chemical structure of ER-819531 (epi-C23 diol) is shown below.



ER-819531
(Epi-C23 Diastereomer)

[0073] B. Single Crystal X-Ray Determination of ER-819531 (epi-C23 diol)

Monohydrate

[0074] A portion of sample ER-819531 was dissolved in a mixture of acetonitrile, several drops of toluene, and one drop of water. This was then allowed to slowly evaporate in a small vial. This resulted in single crystals, one of which was chosen to be used in this study. A colorless block crystal with dimensions 0.12 x 0.12 x 0.04 mm was mounted on a 0.2 mm nylon loop using very small amount of paratone oil. The single crystal structure, shown in Fig. 3-A, was determined using the procedure described above. Table 5 lists the crystal data and structure refinement parameters used to determine the single crystal structure of ER-819531 monohydrate. The structure was solved in the space group $P2_12_12_1$ (# 19) by analysis of systematic absences. All non-hydrogen atoms are refined anisotropically. Hydrogens were calculated by geometrical methods and refined as a riding model. The Flack parameter was used to analyze the crystal. If the Flack parameter value is near zero, the absolute structure given by the structure element refinement is likely correct; if the value is near 1.0, then the inverted structure (the other enantiomer) is likely correct; if the value is near 0.5, the crystal is likely racemic. See Flack, H. D., *Acta Cryst. A* **39**, 1983, 876--881. The Flack parameter was refined to 0.50(16). The chirality of this compound was confirmed by its synthetic source. The crystal used for the diffraction study showed no decomposition during data collection. All drawing are done at 50% ellipsoids. Fig. 3-B is the crystal packing diagram along the b-axis which shows the hydrogen bonding within the crystal, dotted lines

Table 5. Crystal data and structure refinement for ER-819531 monohydrate

Empirical formula	$C_{40}H_{60}O_{13}$	
Formula weight	748.88	
Temperature	193(2) K	
Wavelength	0.71073 Å	
Crystal system	Orthorhombic	
Space group	P2(1)2(1)2(1)	
Unit cell dimensions	$a = 9.6545(16)$ Å	$\alpha = 90^\circ$.
	$b = 11.6562(19)$ Å	$\beta = 90^\circ$.
	$c = 33.618(6)$ Å	$\gamma = 90^\circ$.
Volume	$3783.1(11)$ Å ³	
Z	4	
Density (calculated)	1.315 Mg/m ³	
Absorption coefficient	0.097 mm ⁻¹	
F(000)	1616	
Crystal size	0.12 x 0.12 x 0.04 mm ³	
Theta range for data collection	1.85 to 23.25°.	
Index ranges	-10 ≤ h ≤ 10, -12 ≤ k ≤ 12, -37 ≤ l ≤ 25	
Reflections collected	18298	
Independent reflections	5420 [R(int) = 0.0866]	
Completeness to theta = 23.25°	100.0 %	
Absorption correction	None	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	5420 / 0 / 482	
Goodness-of-fit on F ²	1.025	
Final R indices [I > 2σ(I)]	R1 = 0.0670, wR2 = 0.1275	
R indices (all data)	R1 = 0.1032, wR2 = 0.1421	
Absolute structure parameter	0.5(16)	
Largest diff. peak and hole	0.503 and -0.261 e.Å ⁻³	

[0075] C. X-ray Powder Diffraction (XRPD) Characterization of ER-819531 (epi-C23 diol) Monohydrate

[0076] The XRPD of ER-819531 monohydrate was obtained as described above. The XRPD pattern is shown in Fig. 3-C. Table 6 shows the list of peaks with relative intensities in the XRPD pattern.


Table 6. XRPD Peaks of ER-819531 (epi-C23 diol)	
Position (2 θ)	Rel. Int. (%)
20.6	100.0%
17.2	91.9%
16.1	83.1%
24.4	77.9%
17.8	77.8%
22.1	76.4%
20.0	73.2%
15.2	71.9%
19.1	71.5%
32.1	70.8%
17.3	69.4%
18.6	69.4%
21.4	68.6%
28.2	67.5%
26.2	67.3%
22.7	62.6%
29.2	61.8%
13.1	55.8%
10.5	50.2%
12.3	41.6%
14.4	40.7%
9.6	27.8%
8.1	25.5%

[0077] **Example 4: Characterization of ER-820057 (epi-C23 amine)**

[0078] **A. Preparation of ER-820057 crystal sample**

[0079] ER-820057 is dissolved in acetonitrile (10 vol) at room temperature and the solution is held at room temperature. Crystal growth is observed after 2 hours. Crystal sample

suitable for powder XRPD test was isolated after 16 to 24 hours. The chemical structure of ER-820057 (epi-C23 amine) is shown below.



ER-820057
(Epi-C23 Diastereomer)

[0080] B. X-ray Powder Diffraction (XRPD) Characterization of ER-820057 (epi-C23 amine)

[0081] The XRPD of ER-820057 was obtained as described above. The XRPD pattern is shown in Fig. 4-A. Table 7 shows the list of peaks with relative intensities in the XRPD pattern.


Table 7. XRPD Peaks of ER-820057 (epi-C23 amine)	
Position (2 θ)	Rel. Int. (%)
20.6	108.9%
15.9	100.0%
17.0	96.4%
18.5	93.9%
21.4	87.3%
20.0	85.8%
19.1	84.6%
24.4	84.3%
17.8	80.6%
21.9	74.8%
13.0	73.1%
15.0	66.1%
22.6	65.4%
24.0	63.3%

26.2	62.0%
27.3	60.1%
25.7	56.7%
25.1	55.2%
26.8	55.2%
10.6	50.3%
12.1	48.6%
11.9	45.2%
14.3	44.8%
9.6	36.0%
9.2	35.1%
10.9	31.3%
8.0	29.6%

[0082] **Example 5: Characterization of ER-111197 (epi-C34 diol) Monohydrate**

[0083] **A. Crystallization procedure for the generation of X-ray quality crystal**

[0084] ER-111197 (1 wt) was dissolved in acetonitrile (8 vol). Water (0.8 vol) was added. The solution was left to evaporate at room temperature over 2-3 days. If the crystal does not form, the solution is evaporated to dryness and the procedure is repeated until the crystal forms. The chemical structure of ER-111197 (epi-C34 diol) is shown below.



ER-111197
(Epi-C34 Diastereomer)

[0085] **B. Single Crystal X-Ray Determination of ER-111197 (epi-C34 diol) Monohydrate**

[0086] The colorless needle crystal with dimensions 0.22 x 0.14 x 0.04 mm was mounted on a 0.2 nm nylon loop using very small amount of paratone oil. The single crystal structure,

shown in Fig. 5-A, was determined using the procedure described above. Table 7 lists the crystal data and structure refinement parameters used to determine the single crystal structure of ER-111197 monohydrate. The structure was solved in the space group $P2_12_12_1$ (# 19) by analysis of systematic absences. All non-hydrogen atoms were refined anisotropically. Hydrogens were calculated by geometrical methods and refined as a riding model. The Flack parameter was used to analyze the crystal. If the Flack parameter value is near zero, the absolute structure given by the structure element refinement is likely correct; if the value is near 1.0, then the inverted structure (the other enantiomer) is likely correct; if the value is near 0.5, the crystal is likely racemic. See Flack, H. D., *Acta Cryst. A* **39**, 1983, 876--881. The Flack parameter was refined to 0.3(13). The chirality of this compound was confirmed by its synthetic source. The crystal used for the diffraction study showed no decomposition during data collection. All drawing are done at 50% ellipsoids. Fig. 5-B is the crystal packing diagram along the a-axis which shows the hydrogen bonding within the crystal, dotted lines.

[0087] Table 7. Crystal data and structure refinement for ER-111197 monohydrate

Empirical formula	$C_{40}H_{60}NO_{13}$	
Formula weight	748.88	
Temperature	193(2) K	
Wavelength	0.71073 Å	
Crystal system	Orthorhombic	
Space group	$P2_12_12_1$	
Unit cell dimensions	$a = 9.907(3)$ Å	$\alpha = 90^\circ$.
	$b = 11.212(4)$ Å	$\beta = 90^\circ$.
	$c = 34.483(13)$ Å	$\gamma = 90^\circ$.
Volume	$3830(2)$ Å ³	
Z	4	
Density (calculated)	1.299 Mg/m ³	
Absorption coefficient	0.096 mm ⁻¹	
F(000)	1616	
Crystal size	0.22 x 0.14 x 0.04 mm ³	
Theta range for data collection	1.18 to 27.91°.	
Index ranges	$-13 \leq h \leq 12$, $-14 \leq k \leq 13$, $-42 \leq l \leq 45$	
Reflections collected	27456	

Independent reflections	9109 [R(int) = 0.0720]
Completeness to theta = 27.91°	99.8 %
Absorption correction	None
Max. and min. transmission	0.9962 and 0.9792
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	9109 / 0 / 482
Goodness-of-fit on F ²	0.893
Final R indices [I>2sigma(I)]	R1 = 0.0652, wR2 = 0.1453
R indices (all data)	R1 = 0.1398, wR2 = 0.1659
Absolute structure parameter	0.3(13)
Largest diff. peak and hole	0.911 and -0.346 e.Å ⁻³


[0088] C. Simulated X-ray Powder Diffraction Spectrum of ER-111197 (epi-C34 diol) Monohydrate

[0089] The simulated XRPD spectrum of ER-111197 generated from the single crystal data is shown in Fig. 5-C.

[0090] Example 6: Characterization of ER-809681 (epoxide)

[0091] A. Crystallization procedure for the generation of X-ray quality crystal

[0092] ER-809681-00 (50 mg) was dissolved in dichloromethane (0.25 mL). Pentane (0.5 mL) was added. The solution was stirred until visually homogeneous. The solution was slowly evaporated at room temperature over 18 hours. Crystal suitable for X-ray crystallography study was collected by decanting supernatant liquid. The chemical structure of ER-809681 (epoxide) is shown below.



ER-809681

[0093] B. Single crystal X-ray determination of ER-809681 (epoxide)

[0094] Single crystal X-ray determination method varies from that described above and is detailed in the following section.

[0095] A colorless block crystal of $C_{40}H_{56}O_{11}$ having approximate dimensions of 0.30 x 0.10 x 0.10 mm was mounted on a glass fiber. The single crystal structure is shown in Fig. 6-A. All measurements were made on a Rigaku RAXIS RAPID imaging plate area detector with graphite monochromated Cu-K α radiation. Indexing was performed from 3 oscillations that were exposed for 15 seconds. The crystal-to-detector distance was 127.40 mm. Cell constants and an orientation matrix for data collection corresponded to a primitive orthorhombic cell with dimensions: $a = 9.4700(3) \text{ \AA}$; $b = 17.6327(5) \text{ \AA}$; $c = 23.1790(6) \text{ \AA}$; $V = 3870.47(19) \text{ \AA}^3$. For $Z = 4$ and F.W. = 712.88, the calculated density was 1.223 g/cm^3 . The systematic absences of: $h00: h \neq 2n$; $0k0: k \neq 2n$; $00l: l \neq 2n$ uniquely determine the space group to be: $P2_12_12_1$ (#19). The crystal packing diagram is shown in Fig. 6-B.

[0096] The data were collected at a temperature of $23 \pm 1 \text{ }^\circ\text{C}$ to a maximum 2θ value of 136.5° . A total of 30 oscillation images were collected. A sweep of data was done using ω scans from 80.0 to 260.0° in 30.0° step, at $\chi = 54.0^\circ$ and $\phi = 15.0^\circ$. The exposure rate was $15.0 \text{ [sec./}^\circ]$. A second sweep was performed using ω scans from 80.0 to 260.0° in 30.0° step, at $\chi = 54.0^\circ$ and $\phi = 105.0^\circ$. The exposure rate was $15.0 \text{ [sec./}^\circ]$. Another sweep was performed using ω scans from 80.0 to 260.0° in 30.0° step, at $\chi = 54.0^\circ$ and $\phi = 180.0^\circ$. The exposure rate was $15.0 \text{ [sec./}^\circ]$. Another sweep was performed using ω scans from 80.0 to 260.0° in 30.0° step, at $\chi = 54.0^\circ$ and $\phi = 270.0^\circ$. The exposure rate was $15.0 \text{ [sec./}^\circ]$. Another sweep was performed using ω scans from 80.0 to 260.0° in 30.0° step, at $\chi = 0.0^\circ$ and $\phi = 0.0^\circ$. The exposure rate was $15.0 \text{ [sec./}^\circ]$. The crystal-to-detector distance was 127.40 mm. Readout was performed in the 0.100 mm pixel mode.

[0097] Data Reduction: Of the 16412 reflections that were collected, 934 were unique ($R_{\text{int}} = 0.043$); equivalent reflections were merged. The linear absorption coefficient, μ , for Cu-K α radiation is 7.229 cm^{-1} . An empirical absorption correction was applied which resulted in transmission factors ranging from 0.748 to 0.930. The data were corrected for Lorentz and polarization effects.

[0098] Structure Solution and Refinement: The structure was solved by direct methods (SHELX97: Sheldrick, G.M. (1997)) and expanded using Fourier techniques. See DIRDIF99: Beurskens, P.T., Admiraal, G., Beurskens, G., Bosman, W.P., de Gelder, R., Israel, R. and Smits, J.M.M.(1999), "The DIRDIF-99 program system, Technical Report of the Crystallography Laboratory," University of Nijmegen, The Netherlands. The non-hydrogen atoms were refined anisotropically. Hydrogen atoms were refined using the riding model. The final cycle of full-matrix least-squares refinement on F^2 , depicted as $\sum w(F_o^2 - F_c^2)^2$ where w = least squares weights, was based on 7045 observed reflections and 461 variable parameters. It converged (largest parameter shift was 0.01 times its esd) with unweighted and weighted agreement factors of: $R1 = \sum ||F_o| - |F_c|| / \sum |F_o| = 0.0630$ and $wR2 = [\sum (w (F_o^2 - F_c^2)^2) / \sum w(F_o^2)^2]^{1/2} = 0.2168$.

[0099] The standard deviation of an observation of unit weight was 1.10, with the standard deviation of an observation of unit weight calculated as $[\sum w(F_o^2 - F_c^2)^2 / (N_o - N_v)]^{1/2}$, where: N_o = number of observations and N_v = number of variables. The maximum and minimum peaks on the final difference Fourier map corresponded to 0.20 and -0.28 $e^-/\text{\AA}^3$, respectively.

[00100] Neutral atom scattering factors were taken from Cromer and Waber; "International Tables for X-ray Crystallography", Vol. IV, The Kynoch Press, Birmingham, England, Table 2.2 A (1974). Anomalous dispersion effects were included in F_{calc} (see Ibers, J. A. & Hamilton, W. C.; Acta Crystallogr., 17, 781 (1964)), and the values for $\Delta f'$ and $\Delta f''$ were obtained from Creagh, D. C. & McAuley, W.J. ; "International Tables for Crystallography", Vol C, (A.J.C. Wilson, ed.), Kluwer Academic Publishers, Boston, Table 4.2.6.8, pages 219-222 (1992). The values for the mass attenuation coefficients were taken from Creagh, D. C. & Hubbell, J.H.; "International Tables for Crystallography", Vol C, (A.J.C. Wilson, ed.), Kluwer Academic Publishers, Boston, Table 4.2.4.3, pages 200-206 (1992). All calculations were performed using the CrystalStructure crystallographic software package. See CrystalStructure 3.7.0: Crystal Structure Analysis Package, Rigaku and Rigaku/MSD (2000-2005), 9009 New Trails Dr. The Woodlands TX 77381 USA; and CRYSTALS Issue 10: Watkin, D.J., Prout, C.K. Carruthers, J.R. & Betteridge, P.W., Chemical Crystallography Laboratory, Oxford, UK. (1996). The exception to this was the calculations for refinement, which was performed using SHELX97: Sheldrick, G.M. (1997).

Crystal Data:

Empirical Formula	C ₄₀ H ₅₆ O ₁₁
Formula Weight	712.88
Crystal Color, Habit	colorless, block
Crystal Dimensions	0.30 X 0.10 X 0.10 mm
Crystal System	orthorhombic
Lattice Type	Primitive
Indexing Images	3 oscillations @ 15.0 seconds
Detector Position	127.40 mm
Pixel Size	0.100 mm
Lattice Parameters	a = 9.4700(3) Å b = 17.6327(5) Å c = 23.1790(6) Å V = 3870.47(19) Å ³
Space Group	P2 ₁ 2 ₁ 2 ₁ (#19)
Z value	4
D _{calc}	1.223 g/cm ³
F ₀₀₀	1536.00
μ(CuK _α)	7.229 cm ⁻¹

Intensity Measurements:

Diffractometer	Rigaku RAXIS-RAPID
Radiation	CuK _α (λ = 1.54187 Å) graphite monochromated
Detector Aperture	460 mm x 256 mm
Data Images	30 exposures
ω oscillation Range (χ=54.0, φ=15.0)	80.0 - 260.0°
Exposure Rate	15.0 sec./°
ω oscillation Range (χ=54.0, φ=105.0)	80.0 - 260.0°
Exposure Rate	15.0 sec./°
ω oscillation Range (χ=54.0, φ=180.0)	80.0 - 260.0°
Exposure Rate	15.0 sec./°
ω oscillation Range (χ=54.0, φ=270.0)	80.0 - 260.0°
Exposure Rate	15.0 sec./°
ω oscillation Range (χ=0.0, φ=0.0)	80.0 - 260.0°
Exposure Rate	15.0 sec./°
Detector Position	127.40 mm
Pixel Size	0.100 mm
2θ _{max}	136.5°

No. of Reflections Measured	Total: 16412
Corrections	Unique: 37266 ($R_{\text{int}} = 0.043$) Lorentz-polarization Absorption (trans. factors: 0.748 - 0.930)
Structure Solution and Refinement:	
Structure Solution	Direct Methods (SHELX97)
Refinement	Full-matrix least-squares on F^2
Function Minimized	$\sum w (F_o^2 - F_c^2)^2$
Least Squares Weights	$w = 1 / [\sigma^2(F_o^2) + (0.0877 \cdot P)^2 + 1.4243 \cdot P]$ where $P = (\text{Max}(F_o^2, 0) + 2F_c^2)/3$
$2\theta_{\text{max}}$ cutoff	136.5°
Anomalous Dispersion	All non-hydrogen atoms
No. Observations (All reflections)	7045
No. Variables	461
Reflection/Parameter Ratio	15.28
Residuals: R_1 ($I > 2.00\sigma(I)$)	0.0630
Residuals: R (All reflections)	0.1326
Residuals: wR_2 (All reflections)	0.2168
Goodness of Fit Indicator	1.103
Max Shift/Error in Final Cycle	0.014
Maximum peak in Final Diff. Map	0.20 e-/Å ³
Minimum peak in Final Diff. Map	-0.28 e-/Å ³

[00101] C. X-ray Powder Diffraction (XRPD) Characterization of ER-809681 (epoxide)

[00102] The XRPD collection method for this compound varies from the method described above only in the theta scan range, 2-70 °. The XRPD pattern is shown in Fig. 6-C.

Table 8. XRPD Peaks of ER-809681 (epoxide)	
Position (2θ)	Rel. Int. (%)
16.2	100.0
15.8	60.3
13.9	45.3
19.9	40.8
9.3	39.1

22.1	36.8
20.7	34.9
17.1	33.4
6.5	33.0
21.8	32.3
18.1	26.0
21.4	22.0
14.4	21.2
10.2	21.0
18.9	19.6
15.4	19.4
12.2	15.1

[00103] D. Simulated XRPD Spectrum

[00104] The simulated XRPD pattern generated from the single crystal data is shown in Fig 6-D.

[00105] Example 7: Anti-cancer Activity

[00106] The anti-cancer activity of the compounds described above, in the crystalline forms described, was determined using cell growth inhibition assays as described in Liu, J. et al. Anticancer Research, 27:1509-1511 (2007). The activity data in terms of IC₅₀ nM is described below in Table 9. MES-SA and MES-SA/Dx5-Rx1 uterine sarcoma, were obtained from the American Type Culture Collection and grown in the recommended conditions.

[00107] Cell Growth Inhibition Assays. Cells were seeded at 7.5×10^3 cells/well in 96-well plates in the recommended medium supplemented with 10% FBS and penicillin, streptomycin and L-glutamine. After 4 hours incubation, the test compound was added to each well to give a series of concentrations ranging from 0 to 10 μ M. The cultures were incubated for 4 days at 37°C. The cell growth was determined using modifications (see Finlay G. J., et al. "A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells." Anal Biochem 139: 272-277, 1984) of a methylene blue-based microculture assay (See Towle M. J., et al. "In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B."

Cancer Res 61: 1013-1021, 2001). The medium was removed and the cells were stained with 100 µl of methylene blue (500 µg/ml) for 45 min. After a wash with water, the stained cells were dissolved into 100 µl of sarcosine (1 mg/ml) for 90 min with gentle shaking. The plates were read at $A_{600} - A_{405}$.


[00108] Susceptibility of compound to P-glycoprotein-mediated multidrug resistance (MDR). A pair of human uterine sarcoma cell lines was used: MES-SA, the MDR negative parental cell line, and Dx5-Rx1, a cell line derived from MES-SA after long term of exposure to doxorubicin. This subline expresses P-Glycoprotein at high levels. Both cell lines were seeded at 7.5×10^3 cells/well in McCoy's 5A supplemented with 10% FBS and penicillin, streptomycin and L-glutamine and cell growth was measured as above. The ratio of the IC_{50} values obtained in the parental and resistant cell lines was termed fold resistance and provided an indication of compound susceptibility to P-glycoprotein-mediated MDR against the two cell lines were compared with each other.

Table 9


Crystalline Form:	Example	Activity Data (IC_{50} nM)		Ratio of DxR-Rx1 / MES-SA
		MES-SA	Dx5-Rx1	
ER-076349 monohydrate	1	0.03	6.5	217
ER-818906 (epi-C20 diol) mono-acetonitrile solvate	2	0.96	75	78
ER-819531 (epi-C23 diol) monohydrate	3	1.4	330	236
ER-820057 (epi-C23 amine)	4	3.3	1000	303
ER-111197 (epi-C34 diol) monohydrate	5	0.23	43	186
ER-809681 (epoxide)	6	0.23	2.81	12

The claimed invention is:


1. A crystalline monohydrate of the compound:




2. The crystalline monohydrate of claim 1, characterized by a powder x-ray diffraction pattern having peaks at $9.3^{\circ}2\theta \pm 0.2^{\circ}2\theta$, $10.4^{\circ}2\theta \pm 0.2^{\circ}2\theta$, and $13.0^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
3. The crystalline monohydrate of claim 2, further characterized by a differential scanning calorimetry thermogram having an onset temperature ranging from about 157 to about 161 $^{\circ}\text{C}$.
4. A pharmaceutical composition, comprising a therapeutically effective amount of the crystalline monohydrate of claim 1 and a pharmaceutically acceptable carrier.
5. A composition of claim 4, further comprising a chemotherapeutic drug.
6. The composition of claim 5, wherein said chemotherapeutic drug is selected from the group consisting of antimetabolites, antibiotics, alkylating agents, plant alkaloids, and hormonal agents.
7. A crystalline form of the compound:




8. The crystalline form of the compound of claim 7, characterized by a powder x-ray diffraction pattern having peaks at $6.5^{\circ}2\theta \pm 0.2^{\circ}2\theta$, $9.3^{\circ}2\theta \pm 0.2^{\circ}2\theta$, and $17.1^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
9. A crystalline form of the compound:




10. The crystalline form of the compound claim 9, characterized by a powder x-ray diffraction pattern having peaks at $13.0^{\circ}2\theta \pm 0.2^{\circ}2\theta$, $15.0^{\circ}2\theta \pm 0.2^{\circ}2\theta$, and $15.9^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
11. A pharmaceutical composition, comprising a therapeutically effective amount of a crystalline form of the compound of claim 9 and a pharmaceutically acceptable carrier.
12. The crystalline mono-acetonitrile solvate of the compound:



13. The crystalline solvate claim 12, characterized by a powder x-ray diffraction pattern having peaks at $7.9^{\circ}2\theta \pm 0.2^{\circ}2\theta$, $23.7^{\circ}2\theta \pm 0.2^{\circ}2\theta$, $32.8^{\circ}2\theta \pm 0.2^{\circ}2\theta$, and $40.0^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
14. The crystalline monohydrate of the compound:



15. The crystalline monohydrate of claim 14, wherein the crystalline monohydrate is in a racemic form.
16. The crystalline monohydrate of claim 14, characterized by a powder x-ray diffraction pattern having peaks at $8.1^{\circ}2\theta \pm 0.2^{\circ}2\theta$, $13.1^{\circ}2\theta \pm 0.2^{\circ}2\theta$, and $14.3^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
17. A pharmaceutical composition, comprising a therapeutically effective amount of the crystalline monohydrate of claim 14 and a pharmaceutically acceptable carrier.
18. The crystalline monohydrate of the compound:



19. The crystalline monohydrate of claim 18, characterized by a powder x-ray diffraction pattern having peaks at $8.3^{\circ}2\theta \pm 0.2^{\circ}2\theta$, $15.8^{\circ}2\theta \pm 0.2^{\circ}2\theta$, and $16.6^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
20. A pharmaceutical composition, comprising a therapeutically effective amount of the crystalline monohydrate of claim 18 and a pharmaceutically acceptable carrier.